Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
CARsgen Announces Data of Allogeneic BCMA CAR-T Cell Therapy CT0596 for Relapsed/Refractory Multiple Myeloma at the 2025 ASH Annual Meeting 2025-12-08 10:08
CARsgen Announces Data of Allogeneic BCMA CAR-T Cell Therapy CT0596 for Relapsed/Refractory Multiple Myeloma at the 2025 ASH Annual Meeting 2025-12-08 08:15
CARsgen's CAR-T Product Zevor-Cel Included in China's Commercial Health Insurance Innovative Drug Catalogue 2025-12-07 17:21
CARsgen Announces Positive Clinical Data for Allogeneic CAR-T Products CT0596 and CT1190B 2025-11-03 22:15
CARsgen Presents Preliminary Results on Satri-cel for Adjuvant Therapy of Pancreatic Cancer at ESMO Congress 2025 2025-10-20 08:15
Case Report | Preliminary Clinical Data of CARsgen's Allogeneic BCMA CAR-T Product CT0596 for the Treatment of Primary Plasma Cell Leukemia 2025-10-19 14:00
CARsgen Presents Results on GPRC5D CAR-T CT071 in The Lancet Haematology 2025-10-08 08:15
CARsgen Presents Updated Long-term Follow-up Results for Zevor-cel at IMS 2025 2025-09-18 08:15
CARsgen Therapeutics Announces 2025 Interim Results 2025-08-15 08:15
CARsgen Successfully Defends Its GPC3 CAR-T Patent at the EPO 2025-07-14 08:00
CARsgen Presents Research Results on Satri-cel in The Lancet and at the 2025 ASCO Annual Meeting 2025-06-02 08:15
CARsgen's Satri-cel Granted Priority Review by the NMPA 2025-05-28 12:10
CARsgen's Satri-cel Abstract Available on ASCO Website 2025-05-23 08:00
CARsgen Announces Preliminary Clinical Data for Allogeneic BCMA CAR-T CT0596, Demonstrating Favorable Safety and Efficacy 2025-05-12 08:00
CARsgen Announced 2024 Annual Results 2025-03-19 08:15
CARsgen's Claudin18.2 CAR-T Therapy Satri-cel Granted Breakthrough Therapy Designation by the NMPA 2025-03-03 08:15
CARsgen's Allogeneic CD19/CD20 CAR-T Therapy Administers First Dose in a Patient with Autoimmune Disease 2025-02-28 08:15
CARsgen Therapeutics Introduced Zhuhai SB Xinchuang to Accelerate Allogeneic CAR-T Cell Products Development in Mainland China 2025-02-25 21:00
CARsgen's First Enrolled Subject in the THANK-u Plus™ Platform-Based Allogeneic CAR-T Trial Achieves sCR at Week 4 2025-02-10 08:29
CARsgen's Allogeneic CD38 CAR-T Therapy Administers First Dose in an Investigator-Initiated Trial 2025-01-20 21:50
1 2 3 4